SEC Tracker
Get the app

Synlogic SYBX

Synlogic files 425 related to merger with Caldera

Merger communication

Form
425
Filed
Importance
Routine
  1. Caldera published data from CLD-423 Phase 1a trial showing favorable tolerability and immunogenicity
  2. Caldera expanded pipeline with exclusive license for IL-17 x TL1A bispecific antibody program
  3. Phase 2 trials for CLD-423 in ulcerative colitis and Crohn's disease planned for early 2027

Written from the 425 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Synlogic files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Matinas BioPharma Holdings MTNB public float $5M, Jun 30, 2025
  2. China Pharma Holdings CPHI public float $4M, Jun 30, 2025
  3. Soligenix SNGX public float $5M, Jun 30, 2025
  4. Target Group CBDY public float $5M, Jun 30, 2025
  5. Creative Medical Technology Holdings CELZ public float $5M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.